LAS VEGAS, Nov. 15, 2021 /PRNewswire/ -- DelveInsight's Autoinjectors Market Insights and Forecastreport provides the current and forecast Autoinjectors market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Autoinjectors market.
As per an analysis by DelveInsight, North America is expected to dominate the overall Autoinjectors market during the forecast period.
Major pharma players working proactively in the Autoinjectors market include BD, Ysmoed AG, Sonceboz, Phillips-Medisize, Nemera, Novartis, Teva Pharmaceuticals, Amgen, GSK, Mylan Inc, Elcam Medical, Union Medico Injection Safety ApS, SHL Medical AG, Haselmeier, Owen Mumford Ltd, and others.
DelveInsight estimates that Global Autoinjectors Market is expected to grow at an escalated CAGR of 20.50% during the forecast period from 2021 to 2026 and is anticipated to reach USD 5.51 billion by 2026.
On October 21, 2019, Becton, Dickinson and Company had announced the launch of BD Intevia™ 1mL two-step disposable autoinjector, a platform device combining Autoinjectors and pre-fillable syringe in an integrated system.
On November 23, 2021, Owen Mumford Pharmaceutical Services had announced the launch of the Aidaptus Auto-Injector Platform after the successful completion of the development of the product.
On May 28, 2021, Phillips-Medisize, a Molex company, announced the launch of Aria Smart Autoinjector Platform comprising a smart injection device and a reusable electronic drive unit and a single-use, disposable cassettes.
An Autoinjector is a syringe-like device that comprises a spring-charged needle and has a pre-discharged dosage of drugs. Autoinjectors are used to administer a specific amount of drug when it is pushed into the body in a sliding motion. The devices are majorly utilised in the self-administration of epinephrine for preventing anaphylaxis by patients suffering from migraine (to obtain immediate pain relief) and for medical and emergency treatments. Generally, most Autoinjectors used are one-use, disposable and single-loaded syringes. Dependent on the design, Autoinjector devices are easy to use, self-administered by patients and can be administered by untrained personnel.
To pick on the latest highlights related to Autoinjectors, get the snapshot of the key highlights entailed in the Autoinjectors Marketreport.
Geographically, the global Autoinjectors market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America tends to lead the global market in the present scenario. It is expected that it will continue to remain superior during the forecast period. However, the domination exhibited by North America will be conspicuously challenged by the European market. This domination is attributed to the factors like rising prevalence of chronic conditions such as diabetes and multiple sclerosis, the growing availability of generic auto-injectors, and favourable reimbursement policies
Several recent developments, such as product launches, are also driving the market growth; for instance, on April 27, 2020, Teva Pharmaceuticals announced the launch of an Autoinjector for Ajovy injection in the United States. Also, on July 08, 2021, Otsuka Pharmaceutical Co., Ltd. had received the manufacturing and marketing approval of AJOVY Subcutaneous Injection 225 mg autoinjector in Japan. Moreover, on July 09, 2019, Sandoz had announced the United States retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections. Symjepi is a small, single-dose, pre-filled device and device combination that can be used in place of epinephrine Autoinjectors pertaining to the emergency treatment of allergic reactions.
Owing to the rising prevalence of diabetes cases, rising prevalence of chronic diseases such as multiple sclerosis, there will be an increasing demand that will be experienced in the arena of Autoinjectors. Apart from these factors, an increase in technologically advanced Autoinjectors, an increase in the incidence of anaphylactic shock, an increase in awareness ofAutoinjectors and the easy usability of self-administering injection all contribute to the rise in the growth of the Autoinjectors market.
Some of the Autoinjector market setbacks include alternative invasive & painful drug delivery devices and single designed autoinjectors for multiple drug deliveries. The market for Autoinjectors had observed a period of stagnant growth owing to the outbreak of COVID-19, which gave rise to factors like lockdown restrictions, patient reluctanceto visit the hospitals and clinics, logistical restrictions, unavailability of medical devices and the closing down of manufacturing facilities.
DelveInsight's 'Ultra-Large Volume Wearable Injectors Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of Ultra-Large Volume Wearable Injectors and the historical and forecasted Ultra-Large Volume Wearable Injectors market trends, market drivers, market barriers and key companies involved such as Gerresheimer AG, Enable Injections, Amgen Inc, Insuet Corporation, West Pharmaceutical Services, Tandem Diabetes Care, Ypsomed, CeQur SA, Becton, Dickinson and Company, and many others.
DelveInsight's 'Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as key companies involved in pipelines such as CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others.
DelveInsight's 'Needle Free Injections -Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Needle Free Injections and the historical and forecasted Needle Free Injections market trends, market drivers, market barriers and key companies involved such as Bioject Medical Technologies Inc, Medical International Technology, INJEX Pharma AG, National Medical Products Inc, Valeritas, European Pharma Group, PenJet Corporation, and others.
Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026. The report delivers an in-depth understanding of Injectable Drug Delivery Devices and the historical and forecasted market trends, market drivers, market barriers and key companies involved such as Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie Inc, Pfizer Inc, Mylan N.V. and others.
Browse Through Our Blog Posts
Evaluating the Role of Digital Therapeutics as an Alternative to Conventional Therapies for Depression